Results of induction therapy and outcome of BCR-ABL positive and negative c-ALL and pre-B ALL patients
| . | BCR-ABL− patients n = 257 (%) . | BCR-ABL+ patients n = 175 (%) . | P χ2 . |
|---|---|---|---|
| Results of induction therapy | |||
| CR | 217 (84.6) | 120 (68.4) | .001 |
| Failure | 19 (7) | 32 (18) | |
| Aplasia | 2 (1) | 3 (2) | |
| Early death | 14 (5) | 19 (11) | |
| Withdrawal | 4 (2) | 0 | |
| Not evaluable | 1 (0.4) | 1 (0.6) | |
| Outcome of CR patients | N = 217 (%) | N = 120 (%) | |
| CCR | 109 (50) | 20 (17) | |
| Death in CR | 18 (8) | 26 (21) | |
| Relapse | 90 (42) | 74 (62) |
| . | BCR-ABL− patients n = 257 (%) . | BCR-ABL+ patients n = 175 (%) . | P χ2 . |
|---|---|---|---|
| Results of induction therapy | |||
| CR | 217 (84.6) | 120 (68.4) | .001 |
| Failure | 19 (7) | 32 (18) | |
| Aplasia | 2 (1) | 3 (2) | |
| Early death | 14 (5) | 19 (11) | |
| Withdrawal | 4 (2) | 0 | |
| Not evaluable | 1 (0.4) | 1 (0.6) | |
| Outcome of CR patients | N = 217 (%) | N = 120 (%) | |
| CCR | 109 (50) | 20 (17) | |
| Death in CR | 18 (8) | 26 (21) | |
| Relapse | 90 (42) | 74 (62) |
Early death is death in less than 56 days.
N indicates number of evaluable patients; CCR, continuous CR.